Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jessica Kaufeld

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Plos One|September 15, 2010
Cofilin-1 inactivation leads to proteinuria--studies in zebrafish, mice and humansSharon Ashworth, Beina Teng, Jessica Kaufeld, et al.
Frontiers in Medicine|May 13, 2022
Patients With Infantile Nephropathic Cystinosis in Germany and Austria: A Retrospective Cohort StudyNina O'Connell, Jun Oh, Klaus Arbeiter, et al.
Diagnostics (Basel, Switzerland)|February 25, 2022
An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney TransplantationLisa K Seiler, Ngoc Linh Phung, Christoph Nikolin, et al.
Journal of Thrombosis and Haemostasis : JTH|January 9, 2022
Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpuraLucas Kühne, Jessica Kaufeld, Linus A Völker, et al.
Lancet (London, England)|January 30, 2026
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198Howard Trachtman, Matthias Kretzler, Loreto Gesualdo, et al.
Clinical Pharmacology and Therapeutics|March 22, 2020
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2022
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
Blood|June 5, 2024
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchangeLucas Kühne, Paul Knöbl, Kathrin Eller, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Plos One|September 15, 2010
Cofilin-1 inactivation leads to proteinuria--studies in zebrafish, mice and humansSharon Ashworth, Beina Teng, Jessica Kaufeld, et al.
Frontiers in Medicine|May 13, 2022
Patients With Infantile Nephropathic Cystinosis in Germany and Austria: A Retrospective Cohort StudyNina O'Connell, Jun Oh, Klaus Arbeiter, et al.
Diagnostics (Basel, Switzerland)|February 25, 2022
An Antibody-Aptamer-Hybrid Lateral Flow Assay for Detection of CXCL9 in Antibody-Mediated Rejection after Kidney TransplantationLisa K Seiler, Ngoc Linh Phung, Christoph Nikolin, et al.
Journal of Thrombosis and Haemostasis : JTH|January 9, 2022
Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpuraLucas Kühne, Jessica Kaufeld, Linus A Völker, et al.
Lancet (London, England)|January 30, 2026
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198Howard Trachtman, Matthias Kretzler, Loreto Gesualdo, et al.
Clinical Pharmacology and Therapeutics|March 22, 2020
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2022
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS)Malte Lenders, Peter Nordbeck, Christine Kurschat, et al.
Blood|June 5, 2024
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchangeLucas Kühne, Paul Knöbl, Kathrin Eller, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Pageof 4